PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

(MedPage Today) — A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.
Treatment with rucaparib (Rubraca) led to a median progression-free survival…
Read More

Leave a Reply

%d bloggers like this: